Atreca to Host Virtual R&D Day on Tuesday, April 5, 2022
23 3월 2022 - 9:00PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
it will host a virtual R&D Day on Tuesday, April 5, 2022, at
4:15 p.m. EDT, focused on the Company’s preclinical pipeline
programs in oncology.
Presenters:
- John Orwin, Chief Executive Officer
- Tito Serafini, PhD, Chief Strategy Officer and
Founder
- Daniel Emerling, PhD, Senior Vice President,
Research and Co-Founder
- Amy Manning-Bog, PhD, Vice President,
Translational Sciences
- Shaun Lippow, PhD, Vice President, Protein
Engineering
- Alexander Scholz, PhD, Senior Director,
In-Vitro Pharmacology
The presentation will be followed by a live question and answer
session. To register for the event, please click here.
Conference Call and Webcast InformationThe live
webcast, including accompanying slides, can be accessed through the
Events & Presentations section of the Company's website at
https://ir.atreca.com/news-and-events/event-calendar. To access the
event by telephone, please dial (800) 373-6606 (United States) or
(409) 937-8918 (international) and reference the conference ID
3490903. An archived replay of the webcast will be available on the
Company's website following the live event.
About Atreca, Inc.Atreca is a biopharmaceutical
company developing novel antibody-based immunotherapeutics
generated by its differentiated discovery platform. Atreca's
platform allows access to an unexplored landscape in oncology
through the identification of unique antibody-target pairs
generated by the human immune system during an active immune
response against tumors. These antibodies provide the basis for
first-in-class therapeutic candidates, such as our lead product
candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in
multiple solid tumor cancers is currently enrolling patients. For
more information on Atreca, please visit www.atreca.com.
Forward-Looking StatementsStatements contained
in this press release regarding matters that are not historical
facts are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements regarding our strategy and future plans, including
statements regarding the development of ATRC-101 and our
preclinical and clinical plans and the timing thereof. Our actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the initiation, timing, progress and results of our research and
development programs, preclinical studies, clinical trials,
regulatory submissions, and other matters that are described in our
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (SEC) and
available on the SEC's website at www.sec.gov, including the risk
factors set forth therein. Investors are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial
Officerinfo@atreca.comInvestors:Alex Gray,
650-779-9251agray@atreca.com
Media:Rachel Ford Hutman,
301-801-5540Rachel@fordhutmanmedia.com
Source: Atreca, Inc.
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Atreca (NASDAQ:BCEL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024